Role of miRNAs in endometrial cancer

Histology and Histopathology

Volumn 30, Issue 5, 2015, Pages 539-548

  Li, Shuangdi ^a   Zhang, Jiarong ^a   Wan, Xiaoping ^b  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b Shanghai First Maternity and Infant Health Hospital   (China)

Author keywords

Endometrial cancer; Estrogen receptor; Metastasis; MicroRNA; P53

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; MEMBRANE PROTEIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE; PTEN PROTEIN, HUMAN; TROPOMYOSIN-RELATED KINASE-B, HUMAN;

DRUG RESISTANCE; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METASTASIS; PROGNOSIS; SIGNAL TRANSDUCTION;

DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE GLYCOPROTEINS; MICRORNAS; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTEIN-TYROSINE KINASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 84929728436     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: 10.14670/HH-30.539     Document Type: Review

References (92)

1. Banno K., Yanokura M., Kisu I., Yamagami W., Susumu N. and Aoki D. (2013). MicroRNAs in endometrial cancer. Int. J. Clin. Oncol. 18, 186-192.
2. Bao W., Qiu H., Yang T., Luo X., Zhang H. and Wan X. (2013a). Upregulation of trkb promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. PLoS One 8, e70616.
3. Bao W., Wang H.H., Tian F.J., He X.Y., Qiu M.T., Wang J.Y., Zhang H.J., Wang L.H. and Wan X.P. (2013b). A trkb-stat3-mir-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol. Cancer 12, 155.
4. Bartel D.P. (2004). Micrornas: Genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
5. Boren T., Xiong Y., Hakam A., Wenham R., Apte S., Wei Z., Kamath S., Chen D.T., Dressman H. and Lancaster J.M. (2008). Micrornas and their target messenger rnas associated with endometrial carcinogenesis. Gynecol. Oncol. 110, 206-215.
6. Cai J., Fang L., Huang Y., Li R., Yuan J., Yang Y., Zhu X., Chen B., Wu J. and Li M. (2013). Mir-205 targets pten and phlpp2 to augment akt signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 73, 5402-5415.
7. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., Iorio M.V., Visone R., Sever N.I. and Fabbri M. (2005). A microrna signature associated with prognosis and progression in chronic lymphocytic leukemia. New Engl. J. Med. 353, 1793-1801.
8. Castilla M.A., Moreno-Bueno G., Romero-Perez L., Van De Vijver K., Biscuola M., Lopez-Garcia M.A., Prat J., Matias-Guiu X., Cano A., Oliva E. and Palacios J. (2011). Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J. Pathol. 223, 72-80.
9. Chang C.J., Chao C.H., Xia W., Yang J.Y., Xiong Y., Li C.W., Yu W.H., Rehman S.K., Hsu J.L., Lee H.H., Liu M., Chen C.T., Yu D. and Hung M.C. (2011). P53 regulates epithelial-mesenchymal transition and stem cell properties through modulating mirnas. Nat. Cell Biol. 13, 317-323.
10. Chen X., Yan Q., Li S., Zhou L., Yang H., Yang Y., Liu X. and Wan X. (2012). Expression of the tumor suppressor mir-206 is associated with cellular proliferative inhibition and impairs invasion in erα-positive endometrioid adenocarcinoma. Cancer Lett. 314, 41-53.
11. Cheung L.W., Hennessy B.T., Li J., Yu S., Myers A.P., Djordjevic B., Lu Y., Stemke-Hale K., Dyer M.D., Zhang F., Ju Z., Cantley L.C., Scherer S.E., Liang H., Lu K.H., Broaddus R.R. and Mills G.B. (2011). High frequency of pik3r1 and pik3r2 mutations in endometrial cancer elucidates a novel mechanism for regulation of pten protein stability. Cancer Discov. 1, 170-185.
12. Choi C.H., Lee J.S., Kim S.R., Kim T.J., Lee J.W., Kim B.G. and Bae D.S. (2010). Clinical significance of pmtor expression in endometrioid endometrial carcinoma. Eur. J. Obstet. Gyn. R. B. 153, 207-210.
13. Chung T.K., Cheung T.H., Huen N.Y., Wong K.W., Lo K.W., Yim S.F., Siu N.S., Wong Y.M., Tsang P.T., Pang M.W., Yu M.Y., To K.F., Mok S.C., Wang V.W., Li C., Cheung A.Y., Doran G., Birrer M.J., Smith D.I. and Wong Y.F. (2009). Dysregulated micrornas and their predicted targets associated with endometrioid endometrial adenocarcinoma in hong kong women. Int. J. Cancer 124, 1358-1365.
14. Chung T.K., Lau T.S., Cheung T.H., Yim S.F., Lo K.W., Siu N.S., Chan L.K., Yu M.Y., Kwong J., Doran G., Barroilhet L.M., Ng A.S., Wong R.R., Wang V.W., Mok S.C., Smith D.I., Berkowitz R.S. and Wong Y.F. (2012). Dysregulation of microrna-204 mediates migration and invasion of endometrial cancer by regulating foxc1. Int. J. Cancer 130, 1036-1045.
15. Cochrane D.R., Spoelstra N.S., Howe E.N., Nordeen S.K. and Richer J.K. (2009). Microrna-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Ther. 8, 1055-1066.
16. Cochrane D.R., Howe E.N., Spoelstra N.S. and Richer J.K. (2010). Loss of mir-200c: A marker of aggressiveness and chemoresistance in female reproductive cancers. J. Oncol. 2010, 821717.
17. Cohn D.E., Fabbri M., Valeri N., Alder H., Ivanov I., Liu C.G., Croce C.M. and Resnick K.E. (2010). Comprehensive mirna profiling of surgically staged endometrial cancer. Am. J. Obstet. Gynecol. 202, 656 e1-8.
18. Colas E., Pedrola N., Devis L., Ertekin T., Campoy I., Martinez E., Llaurado M., Rigau M., Olivan M., Garcia M., Cabrera S., Gil-Moreno A., Xercavins J., Castellvi J., Garcia A., Ramon Cajal S., Moreno-Bueno G., Dolcet X., Alameda F., Palacios J., Prat J., Doll A., Matias-Guiu X., Abal M. and Reventos J. (2012). The emt signaling pathways in endometrial carcinoma. Clin. Transl. Oncol. 14, 715-720.
19. Devor E.J., Hovey A.M., Goodheart M.J., Ramachandran S. and Leslie K.K. (2011). Microrna expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of micrornas. Oncol. Rep. 26, 995.
20. Di Cristofano A. and Ellenson L.H. (2007). Endometrial carcinoma. Annu. Rev. Pathol. 2, 57-85.
21. Diaz-Martin J., Diaz-Lopez A., Moreno-Bueno G., Castilla M.A., Rosa-Rosa J.M., Cano A. and Palacios J. (2014). A core microrna signature associated with inducers of the epithelial-to-mesenchymal transition. J. Pathol. 232, 319-329.
22. Dong P., Kaneuchi M., Watari H., Hamada J., Sudo S., Ju J. and Sakuragi N. (2011). Microrna-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene bmi-1. Mol. Cancer 10, 99.
23. Dong P., Karaayvaz M., Jia N., Kaneuchi M., Hamada J., Watari H., Sudo S., Ju J. and Sakuragi N. (2013). Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the mir-130b-zeb1 axis. Oncogene 32, 3286-3295.
24. Dong P., Kaneuchi M., Watari H., Sudo S. and Sakuragi N. (2014). Microrna-106b modulates epithelial-mesenchymal transition by targeting twist1 in invasive endometrial cancer cell lines. Mol. Carcinogen. 53, 349-359.
25. Duggan B.D., Felix J.C., Muderspach L.I., Tourgeman D., Zheng J. and Shibata D. (1994). Microsatellite instability in sporadic endometrial carcinoma. J. Natl. Cancer. Inst. 86, 1216-1221.
26. Frankel L.B., Christoffersen N.R., Jacobsen A., Lindow M., Krogh A. and Lund A.H. (2008). Programmed cell death 4 (pdcd4) is an important functional target of the microrna mir-21 in breast cancer cells. J. Biol. Chem. 283, 1026-1033.
27. Gao M., Sun P., Wang J., Zhao D. and Wei L. (2006). Expression of estrogen receptor–related receptor isoforms and clinical significance in endometrial adenocarcinoma. Int. J. Gynecol. Cancer 16, 827-833.
28. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W. and Hannon G.J. (2005). A microrna polycistron as a potential human oncogene. Nature 435, 828-833.
29. Hiroki E., Akahira J., Suzuki F., Nagase S., Ito K., Suzuki T., Sasano H. and Yaegashi N. (2010). Changes in microrna expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci. 101, 241-249.
30. Hiroki E., Suzuki F., Akahira J.i., Nagase S., Ito K., Sugawara J.i., Miki Y., Suzuki T., Sasano H. and Yaegashi N. (2012). Microrna‐34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int. J. Cancer 131, E395-E404.
31. Howe E.N., Cochrane D.R. and Richer J.K. (2011). Targets of mir-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res. 13, R45.
32. Huang Y.W., Liu J.C., Deatherage D.E., Luo J., Mutch D.G., Goodfellow P.J., Miller D.S. and Huang T.H. (2009). Epigenetic repression of microrna-129-2 leads to overexpression of sox4 oncogene in endometrial cancer. Cancer Res. 69, 9038-9046.
33. Huang Y.W., Kuo C.T., Chen J.H., Goodfellow P.J., Huang T.H., Rader J.S. and Uyar D.S. (2014). Hypermethylation of mir-203 in endometrial carcinomas. Gynecol. Oncol. 133, 340-345.
34. Hunten S., Siemens H., Kaller M. and Hermeking H. (2013). The p53/microrna network in cancer: Experimental and bioinformatics approaches. Adv. Exp. Med. Biol. 774, 77-101.
35. Huszar M., Pfeifer M., Schirmer U., Kiefel H., Konecny G.E., Ben-Arie A., Edler L., Munch M., Muller-Holzner E., Jerabek-Klestil S., Abdel-Azim S., Marth C., Zeimet A.G., Altevogt P. and Fogel M. (2010). Up-regulation of l1cam is linked to loss of hormone receptors and ecadherin in aggressive subtypes of endometrial carcinomas. J. Pathol. 220, 551-561.
36. Jia W., Wu Y., Zhang Q., Gao G., Zhang C. and Xiang Y. (2013). Identification of four serum micrornas from a genome-wide serum microrna expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer. Oncol. Lett. 6, 261-267.
37. Jiang F., Liu T., He Y., Yan Q., Chen X., Wang H. and Wan X. (2011). Mir-125b promotes proliferation and migration of type ii endometrial carcinoma cells through targeting tp53inp1 tumor suppressor in vitro and in vivo. BMC Cancer 11, 425.
38. Jiang L., Meng W., Zeng J., Hu H. and Lu L. (2013). Mir-34c oligonucleotide enhances chemosensitivity of ishikawa cell to cisplatin by inducing apoptosis. Cell Biol. Int. 37, 577-583.
39. Karaayvaz M., Zhang C., Liang S., Shroyer K.R. and Ju J. (2012). Prognostic significance of mir-205 in endometrial cancer. PLoS One 7, e35158.
40. Klinge C.M. (2012). Mirnas and estrogen action. Trends Endocrin. Met. 23, 223-233.
41. Kong X., Xu X., Yan Y., Guo F., Li J., Hu Y., Zhou H. and Xun Q. (2014). Estrogen regulates the tumour suppressor mirna-30c and its target gene, mta-1, in endometrial cancer. PLoS One 9, e90810.
42. Kuhn E., Wu R.-C., Guan B., Wu G., Zhang J., Wang Y., Song L., Yuan X., Wei L. and Roden R.B. (2012). Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J. Natl. Cancer Inst. 104, 1503-1513.
43. Kuokkanen S., Chen B., Ojalvo L., Benard L., Santoro N. and Pollard J.W. (2010). Genomic profiling of micrornas and messenger rnas reveals hormonal regulation in microrna expression in human endometrium. Biol. Reprod. 82, 791-801.
44. Lam E.W., Shah K. and Brosens J.J. (2012). The diversity of sex steroid action: The role of micro-rnas and foxo transcription factors in cycling endometrium and cancer. J. Endocrinol. 212, 13-25.
45. Le Gallo M., O'Hara A.J., Rudd M.L., Urick M.E., Hansen N.F., O'Neil N.J., Price J.C., Zhang S., England B.M. and Godwin A.K. (2012). Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nature Genet. 44, 1310-1315.
46. Le M.T., Teh C., Shyh-Chang N., Xie H., Zhou B., Korzh V., Lodish H.F. and Lim B. (2009). Microrna-125b is a novel negative regulator of p53. Genes Dev. 23, 862-876.
47. Lee J.W., Park Y.A., Choi J.J., Lee Y.Y., Kim C.J., Choi C., Kim T.J., Lee N.W., Kim B.G. and Bae D.S. (2011). The expression of the mirna-200 family in endometrial endometrioid carcinoma. Gynecol. Oncol. 120, 56-62.
48. Lee H., Choi H.J., Kang C.S., Lee H.J., Lee W.S. and Park C.S. (2012). Expression of mirnas and pten in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Modern Pathol. 25, 1508-1515.
49. Lee T.S., Jeon H.W., Kim Y.B., Kim Y.A., Kim M.A. and Kang S.B. (2013). Aberrant microrna expression in endometrial carcinoma using formalin-fixed paraffin-embedded (ffpe) tissues. PLoS One 8, e81421.
50. Leskela S., Leandro-Garcia L.J., Mendiola M., Barriuso J., Inglada-Perez L., Munoz I., Martinez-Delgado B., Redondo A., de Santiago J., Robledo M., Hardisson D. and Rodriguez-Antona C. (2011). The mir-200 family controls beta-tubulin iii expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr-Related Cancer 18, 85-95.
51. Li S.D., Zhang J.R., Wang Y.Q. and Wan X.P. (2010). The role of micrornas in ovarian cancer initiation and progression. J. Cell. Mol. Med. 14, 2240-2249.
52. Li S., Hu R., Wang C., Guo F., Li X. and Wang S. (2014). Mir-22 inhibits proliferation and invasion in estrogen receptor α-positive endometrial endometrioid carcinomas cells. Mol. Med. Rep. 9, 2393-2399.
53. Liu B., Che Q., Qiu H., Bao W., Chen X., Lu W., Li B. and Wan X. (2014). Elevated mir-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting erα. PLoS One 9, e87563.
54. Ma L., Teruya-Feldstein J. and Weinberg R.A. (2007). Tumour invasion and metastasis initiated by microrna-10b in breast cancer. Nature 449, 682-688.
55. Ma W.J., Lv G.D., Tuersun A., Liu Q., Liu H., Zheng S.T., Huang C.G., Feng J.G., Wang X., Lin R.Y., Sheyhidin I. and Lu X.M. (2011). Role of microrna-21 and effect on pten in kazakh's esophageal squamous cell carcinoma. Mol. Biol. Rep. 38, 3253-3260.
56. McConechy M.K., Ding J., Cheang M.C., Wiegand K.C., Senz J., Tone A.A., Yang W., Prentice L.M., Tse K. and Zeng T. (2012). Use of mutation profiles to refine the classification of endometrial carcinomas. J. Pathol. 228, 20-30.
57. Meng F., Henson R., Lang M., Wehbe H., Maheshwari S., Mendell J.T., Jiang J., Schmittgen T.D. and Patel T. (2006). Involvement of human micro-rna in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130, 2113-2129.
58. Mulrane L., McGee S.F., Gallagher W.M. and O'Connor D.P. (2013). Mirna dysregulation in breast cancer. Cancer Res. 73, 6554-6562.
59. Myatt S.S., Wang J., Monteiro L.J., Christian M., Ho K.K., Fusi L., Dina R.E., Brosens J.J., Ghaem-Maghami S. and Lam E.W. (2010). Definition of micrornas that repress expression of the tumor suppressor gene foxo1 in endometrial cancer. Cancer Res. 70, 367-377.
60. Network C.G.A.R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73.
61. Nishida N., Yokobori T., Mimori K., Sudo T., Tanaka F., Shibata K., Ishii H., Doki Y., Kuwano H. and Mori M. (2011). Microrna mir-125b is a prognostic marker in human colorectal cancer. Int. J. Oncol. 38, 1437-1443.
62. Pan Q., Luo X., Toloubeydokhti T. and Chegini N. (2007). The expression profile of micro-rna in endometrium and endometriosis and the influence of ovarian steroids on their expression. Mol. Hum. Reprod. 13, 797-806.
63. Panda H., Pelakh L., Chuang T.D., Luo X., Bukulmez O. and Chegini N. (2012). Endometrial mir-200c is altered during transformation into cancerous states and targets the expression of zebs, vegfa, flt1, ikkbeta, klf9, and fbln5. Reprod. Sci. 19, 786-796.
64. Pandey D.P. and Picard D. (2009). Mir-22 inhibits estrogen signaling by directly targeting the estrogen receptor α mrna. Mol. Cell. Biol. 29, 3783-3790.
65. Park Y.A., Lee J.W., Choi J.J., Jeon H.K., Cho Y., Choi C., Kim T.J., Lee N.W., Kim B.G. and Bae D.S. (2012). The interactions between microrna-200c and brd7 in endometrial carcinoma. Gynecol. Oncol. 124, 125-133.
66. Qin X., Yan L., Zhao X., Li C. and Fu Y. (2012). Microrna-21 overexpression contributes to cell proliferation by targeting pten in endometrioid endometrial cancer. Oncol. Lett. 4, 1290-1296.
67. Qu C., Liang Z., Huang J., Zhao R., Su C., Wang S., Wang X., Zhang R., Lee M.H. and Yang H. (2012). Mir-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting pten. Cell Cycle 11, 785-796.
68. Ratner E.S., Tuck D., Richter C., Nallur S., Patel R.M., Schultz V., Hui P., Schwartz P.E., Rutherford T.J. and Weidhaas J.B. (2010). Microrna signatures differentiate uterine cancer tumor subtypes. Gynecol. Oncol. 118, 251-257.
69. Schirmer U., Doberstein K., Rupp A.K., Bretz N.P., Wuttig D., Kiefel H., Breunig C., Fiegl H., Muller-Holzner E., Zeillinger R., Schuster E., Zeimet A.G., Sultmann H. and Altevogt P. (2014). Role of mir-34a as a suppressor of l1cam in endometrial carcinoma. Oncotarget 5, 462-472.
70. Sebastianelli A., Renaud M.C., Gregoire J., Roy M. and Plante M. (2010). Preoperative ca 125 tumour marker in endometrial cancer: Correlation with advanced stage disease. J. Obstet. Gynaecol. Can. 32, 856-860.
71. Shang C., Lu Y.M. and Meng L.R. (2012). Microrna-125b downregulation mediates endometrial cancer invasion by targeting erbb2. Med. Sci. Monit.18, BR149-155.
72. Siegel R., Naishadham D. and Jemal A. (2013). Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30.
73. Slomovitz B.M. and Coleman R.L. (2012). The pi3k/akt/mtor pathway as a therapeutic target in endometrial cancer. Clin. Cancer Res. 18, 5856-5864.
74. Snowdon J., Zhang X., Childs T., Tron V.A. and Feilotter H. (2011). The microrna-200 family is upregulated in endometrial carcinoma. PLoS One 6, e22828.
75. Su N., Qiu H., Chen Y., Yang T., Yan Q. and Wan X. (2013). Mir-205 promotes tumor proliferation and invasion through targeting esrrg in endometrial carcinoma. Oncol. Rep. 29, 2297-2302.
76. Torres A., Torres K., Pesci A., Ceccaroni M., Paszkowski T., Cassandrini P., Zamboni G. and Maciejewski R. (2012). Deregulation of mir-100, mir-99a and mir-199b in tissues and plasma coexists with increased expression of mtor kinase in endometrioid endometrial carcinoma. BMC Cancer 12, 369.
77. Torres A., Torres K., Pesci A., Ceccaroni M., Paszkowski T., Cassandrini P., Zamboni G. and Maciejewski R. (2013). Diagnostic and prognostic significance of mirna signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int. J. Cancer 132, 1633-1645.
78. Tsukamoto O., Miura K., Mishima H., Abe S., Kaneuchi M., Higashijima A., Miura S., Kinoshita A., Yoshiura K. and Masuzaki H. (2014). Identification of endometrioid endometrial carcinoma-associated micrornas in tissue and plasma. Gynecol. Oncol. 132, 715-721.
79. Valeri N., Gasparini P., Fabbri M., Braconi C., Veronese A., Lovat F., Adair B., Vannini I., Fanini F., Bottoni A., Costinean S., Sandhu S.K., Nuovo G.J., Alder H., Gafa R., Calore F., Ferracin M., Lanza G., Volinia S., Negrini M., McIlhatton M.A., Amadori D., Fishel R. and Croce C.M. (2010). Modulation of mismatch repair and genomic stability by mir-155. Proc. Natl. Acad. Sci. USA 107, 6982-6987.
80. Wang D., Zheng W., Wang S.M., Wang J.B., Wei W.Q., Liang H., Qiao Y.L. and Boffetta P. (2012). Estimation of cancer incidence and mortality attributable to overweight, obesity, and physical inactivity in china. Nutr. Cancer 64, 48-56.
81. Ward E.C., Hoekstra A.V., Blok L.J., Hanifi-Moghaddam P., Lurain J.R., Singh D.K., Buttin B.M., Schink J.C. and Kim J.J. (2008). The regulation and function of the forkhead transcription factor, forkhead box o1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology 149, 1942-1950.
82. Wu W., Lin Z., Zhuang Z. and Liang X. (2009). Expression profile of mammalian micrornas in endometrioid adenocarcinoma. Eur. J. Cancer Prev. 18, 50-55.
83. Wu Y., Xiao Y., Ding X., Zhuo Y., Ren P., Zhou C. and Zhou J. (2011). A mir-200b/200c/429-binding site polymorphism in the 3' untranslated region of the ap-2alpha gene is associated with cisplatin resistance. PLoS One 6, e29043.
84. Wu D., Huang H.J., He C.N. and Wang K.Y. (2013). Microrna-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mtor). Int. J. Gynecol. Cancer 23, 1191-1197.
85. Xu Y.Y., Wu H.J., Ma H.D., Xu L.P., Huo Y. and Yin L.R. (2013). Microrna-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin d1. FEBS J. 280, 3768-3779.
86. Yeramian A., Moreno-Bueno G., Dolcet X., Catasus L., Abal M., Colas E., Reventos J., Palacios J., Prat J. and Matias-Guiu X. (2013). Endometrial carcinoma: Molecular alterations involved in tumor development and progression. Oncogene 32, 403-413.
87. Zhang S. and Yu D. (2010). Pi(3)king apart pten's role in cancer. Clin. Cancer Res. 16, 4325-4330.
88. Zhang R., He Y., Zhang X., Xing B., Sheng Y., Lu H. and Wei Z. (2012). Estrogen receptor-regulated micrornas contribute to the bcl2/bax imbalance in endometrial adenocarcinoma and precancerous lesions. Cancer Lett. 314, 155-165.
89. Zhang X., Dong Y., Ti H., Zhao J., Wang Y., Li T. and Zhang B. (2013). Down-regulation of mir-145 and mir-143 might be associated with DNA methyltransferase 3b overexpression and worse prognosis in endometrioid carcinomas. Hum. Pathol. 44, 2571-2580.
90. Zhou J., Song T., Gong S., Zhong M. and Su G. (2010). Microrna regulation of the expression of the estrogen receptor in endometrial cancer. Mol. Med. Rep. 3, 387-392.
91. Zhou H., Xu X., Xun Q., Yu D., Ling J., Guo F., Yan Y., Shi J. and Hu Y. (2012). Microrna-30c negatively regulates endometrial cancer cells by targeting metastasis-associated gene-1. Oncol. Rep. 27, 807-812.
92. Zighelboim I., Goodfellow P.J., Gao F., Gibb R.K., Powell M.A., Rader J.S. and Mutch D.G. (2007). Microsatellite instability and epigenetic inactivation of mlh1 and outcome of patients with endometrial carcinomas of the endometrioid type. J. Clin. Oncol. 25, 2042-2048